Alzheimer's Disease
IND-enabling studies underway
Two companion biologics that visualize Alzheimer's with accuracy and treat it at the source — unified by AI. Our published preclinical animal-model data show reversal of cogntive deficits.
Biologic A — Diagnostic
Accurately shows which brain regions are affected and how severely. Readily repeatable studies — No PET isotopes, no invasive procedures.
Biologic B — Treatment
Delivers a therapeutic protein directly and non-invasively to brain. Preclinical animal-model data show reversal of cognitive deficits.
Custom AI Platform
Tracks early warning signs, estimates personalized risk scores, and supports the treatment strategy in real time. Clinician decision support, fully documented.
The approach
Alzheimer's has two devastating problems: we can't see it coming clearly enough, and we can't stop it once it starts. ExQor tackles both simultaneously with a unified system.
The MRI diagnostic biologic reveals exactly where damage is occurring. That scan then drives the treatment — telling us precisely where to target, how much to give, and whether it's working. No guesswork, no population-level dosing.
"Approved antibody therapies such as lecanemab and donanemab are designed to slow progression. ExQor is pursuing a different goal — repair at the source — and our published preclinical animal-model data show reversal of cognitive deficits . Clinical efficacy in humans will be established in our clinical trials."
Both biologics use a clathrin-mediated transport mechanism to cross the blood-brain barrier non-invasively — a platform discovery that underpins the entire system.
Simplified administration. No surgery, no infusion center required — with home-based delivery potential.
MRI scans confirm treatment response over time. Objective evidence, not subjective reporting.
Further enhancing clinician decision support, the AI platform design is open to leading third-party AI systems. For controlling healthcare record security, the platform is open to development of local-only AI systems using open-source software.
Development status
ExQor is in IND-enabling studies targeting Phase 1 first-in-human trials. Our regulatory strategy leverages the diagnostic biologic as the entry point under FDA's companion diagnostic framework, with the treatment biologic following in sequence.
Market & patient impact
For the approximately 55 million people worldwide living with dementia — and the 131.5 million projected by 2050 — ExQor's unified approach aims to shift the treatment paradigm from disease management toward disease modification and repair. This is the program's objective; it has not yet been demonstrated in humans.
MRI diagnostic accessibility and home-based delivery potential could democratize access to advanced neurological care, reducing the global economic burden currently projected to reach $1.6 trillion by 2050. (Source: The Lancet)
Information Technology
ExQor's SDPS (Subject Dimension Progression Score) is its multifunction AI platform turning biomarker data into actionable clinical intelligence. The platform is purpose-built to work alongside the CNS biologics — its clinical deployment in lock step from IND to allowance of the biologics.
The SDPS platform integrates fluid biomarkers, MRI morphometrics, and cognitive composites into a single continuous score that tracks disease progression and treatment response in real time — giving clinicians a unified view of CNS health across every patient visit, with personalized progression tracking.
The SDPS platform's built-in simulation module models trial outcomes across user-defined cohort parameters — giving ExQor a statistical power map before a single patient is enrolled and substantially reducing the time and cost of reaching pivotal endpoints.
A deep-learning imaging pipeline processes conventional MRI acquisitions to automatically extract the contrast signature produced by the ExQor ligand — linking the imaging readout directly to the SDPS score for fully integrated subject monitoring.
Biotechnology
Once dismissed as hardly possible, large-molecule biologics, including growth factors, antibodies, and other large molecule agents now cross the blood-brain barrier naturally — without barrier disruption. In the instance of Alzheimer's disease, ExQor is entering the FDA IND phase with preclinical animal-model evidence that its approach can both detect AD-associated changes and, by delivering brain-derived neurotrophic factor (BDNF) to the brain, reverse cognitive deficits in those models. Clinical efficacy in humans has not yet been established.
BDNF–Clathrin biologic conjugate
Simplified administration for outpatient settings
Clathrin transcytosis across blood-brain barrier
Payload delivered to AD-affected brain regions
SDPS monitoring of treatment = targeted cognitive restoration
The diagnostic biologic is an ExQor MRI ligand that accumulates in AD-affected brain regions. Standard MRI systems — already widely available — can then reveal early signatures of impaired neurogenesis, synaptic loss, and cognitive decline, potentially years before symptoms appear. No PET isotopes, no invasive procedures.
Preclinical studies demonstrated that therapeutic delivery of BDNF via the multi-patented clathrin carrier restored measures of cognitive function in animal models, rather than merely slowing decline. ExQor's goal is disease reversal; translation to humans will be established in clinical trials. .
Preclinical studies completed, ExQor's IND application for treating Alzheimer's is advancing on a clear, credentialed path. The program benefits from an established scientific foundation across both the diagnostic ligand and therapeutic BDNF programs, with regulatory strategy aligned for an efficient transition from IND approval to first-in-human trials. The SDPS clinical trial simulation feature could inform optimal trial outcomes.
Systems Architecture
A platform serving one medical research site and a platform serving every clinic that wants it are two different health care scenarios. Alzheimer's is a disease of years, and the patients who benefit most are the ones followed carefully over those years. Doing that for one clinic is straightforward. Doing it for every clinic that asks, without the quality of care degrading as the number grows, is the harder problem.
ExQor is developing SDPS to be available to every clinic treating Alzheimer's. Its computational layer is licensed from the developer under an arm's-length agreement and is designed for embedded deployment, so that a small memory clinic can run the same platform as a major academic center. What each patient contributes stays under their consent and their clinician's direction; the platform's job is to make that contribution count.
Scans, biomarkers, and assessments the patient has agreed to share
A single clear picture of that patient, in the clinician's hands
The same standard of care wherever the patient is treated
Cognitive decline does not wait for appointments. When a patient chooses to share results gathered between visits, the platform holds the thread — so that a clinician returning to the chart after six months sees a trajectory rather than two disconnected snapshots, and a change worth acting on is visible while there is still time to act.
Advanced neurological care concentrates in large academic hospitals, which is little help to a patient three hours away. The computational layer is designed to run within the resources of a community clinic, and to keep patient data on site where that is the right answer to a privacy or connectivity constraint.
A platform that informs clinical decisions must be able to show its work. SDPS supports the clinician's judgment rather than substituting for it, and is being developed against the documentation, traceability, and treatment expectations that apply to clinical decision-support software under US regulatory frameworks.
We welcome inquiries from partners interested in our CNS diagnostic and therapeutic programs.
Email: info@exqor.com
Tel: +1 (617) 742-4422